title: [Short-term neoadjuvant hormone therapy enhanced expression of clusterin in prostate cancer].
abstract: OBJECTIVE
  To define changes in clusterin expression following short-term neoadjuvant hormone therapy (NHT) and its biological significance in prostate cancer tissues.
  
  
  METHODS
  Twenty-six archival radical prostatectomy (RP) specimens without receiving NHT, 19 needle biopsies and corresponding 19 RP specimens following 3-month NHT, were subjected to immunohistochemical clusterin staining.
  
  
  RESULTS
  Staining for clusterin was mainly found in cytoplasm and part of extracellular matrix. Clusterin expression was significantly greater in RP specimens with preoperative NHT (t = 2.91, P < 0.01); Needle biopsies obtained before NHT consistently demonstrated lower staining intensity (1.42 +/- 0.51) than corresponding RP specimens (2.16 +/- 0.60) following 3-month NHT (t = 7.10, P < 0.01).
  
  
  CONCLUSIONS
  Upregulation of clusterin in part accounts for malignant progression of prostate cancer through its anti-apoptotic action following androgen withdrawal. These findings support that adjuvant therapy targeting clusterin may enhance androgen ablation therapy in advanced prostate cancer.
authors.affiliation: Department of Urology, First Hospital of Peking University, Institute of Urology, Peking University, Beijing 100034, China. farmerniu@163.com
authors.forename: Yi-nong
authors.initials: YN
authors.lastname: Niu
authors.forename: Dian-qi
authors.initials: DQ
authors.lastname: Xin
authors.forename: Zhi-song
authors.initials: ZS
authors.lastname: He
authors.forename: Li-qun
authors.initials: LQ
authors.lastname: Zhou
authors.forename: Bo-nian
authors.initials: BN
authors.lastname: Pan
authors.forename: Yan-qun
authors.initials: YQ
authors.lastname: Na
authors.forename: Ying-lu
authors.initials: YL
authors.lastname: Guo
mesh_terms: D000368:Aged; D051152:Clusterin / Q000235:genetics / Q000378:metabolism*; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D008875:Middle Aged; D020360:Neoadjuvant Therapy / Q000379:methods; D016376:Oligonucleotides, Antisense / Q000627:therapeutic use; D011471:Prostatic Neoplasms / Q000378:metabolism / Q000473:pathology / Q000628:therapy*
chemical_list: D051152:Clusterin; D016376:Oligonucleotides, Antisense